Engineered immune cells take on Hard-to-Treat cancers

NCT ID NCT05120271

Ongoing Disease control Sponsor: Sotio Biotech Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new treatment called BOXR1030 for people with advanced solid tumors that have a specific marker (GPC3). The treatment uses specially designed immune cells given after chemotherapy to help fight the cancer. The main goals are to check safety and find the best dose. About 7 adults aged 18 to 80 with certain cancers like liver or lung cancer are taking part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous neuroendocrine carcinoma hepatocellular carcinoma myxoid liposarcoma myxoid/round cell liposarcoma squamous cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA MERKEL CELL CARCINOMA MYXOID/ROUND CELL LIPOSARCOMA SQUAMOUS CELL CARCINOMA OF THE LUNG

Contacts and locations

Locations

Baylor Scott and White Research Institute

Dallas, Texas, 75246, United States
Beatson Institute for Cancer Research Wolfson Wohl Cancer Research Centre

Glasgow, G61 1BD, United Kingdom
Fred Hutchinson Cancer Center - Seattle Cancer Care Alliance (SCCA) Location

Seattle, Washington, 98109, United States
Froedtert and Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Hoag Hospital Newport Beach

Newport Beach, California, 92663, United States
The Royal Marsden NHS Foundation Trust

London, SW3 6JJ, United Kingdom
University College London Hospitals NHS Foundation Trust

London, NW1 2PG, United Kingdom
University of Texas MD Anderson Cancer Center

Houston, Texas, 77030-4008, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.